vraylar
Preclinical
AbbVievraylar is one of 90 therapeutic programs targeting Bipolar Disorder. It is currently in Preclinical.
2
Indications
0
Total Trials
0
Active Trials
89
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
174 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Jazz PharmaceuticalsPreclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Persantine
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for vraylar. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company